Banque Pictet & Cie’s Ascendis Pharma A/S ASND Stock Holding History

Banque Pictet & Cie’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,997	Closed	-$857K	–	497
2023 Q1	$857K	Sell	7,997 -3,626	-31%	-$415K	0.01%	399
2022 Q4	$1.42M	Sell	11,623 -3,668	-24%	-$426K	0.01%	346
2022 Q3	$1.58M	Sell	15,291 -58	-0.4%	-$5.5K	0.02%	323
2022 Q2	$1.43K	Sell	15,349 -1,476	-9%	-$139K	0.01%	366
2022 Q1	$1.98M	Buy	16,825 +7,846	+87%	+$909K	0.02%	332
2021 Q4	$1.21M	Buy	+8,979	New	+$1.34M	0.01%	437

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Banque Pictet & Cie's ASND Position: Q2 2023 in Review

Banque Pictet & Cie sold out of Ascendis Pharma A/S (ASND) in Q2 2023, closing a stake of 7,997 shares — an estimated $857K sold.

Banque Pictet & Cie first reported a position in ASND in Q4 2021 and held it in 6 quarters. The position peaked at $1.98M in Q1 2022. 158 funds tracked by Wall St. Rank hold ASND as of Q2 2023.

Banque Pictet & Cie reported no remaining Ascendis Pharma A/S position as of Q2 2023 after selling out during the quarter.
Banque Pictet & Cie sold 7,997 Ascendis Pharma A/S shares in Q2 2023, an estimated $857K.
Banque Pictet & Cie first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 6 quarters.
Banque Pictet & Cie's Ascendis Pharma A/S position peaked at $1.98M in Q1 2022.
158 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2023.

Based on Banque Pictet & Cie's 13F filing for Q2 2023, filed 4 Aug 2023.